【摘要】 目的:评价伊立替康(CPT-11)联合氟尿嘧啶(5-FU)与醛氢叶酸(LV)治疗转移性结直肠癌的临床疗效及毒副反应。方法:48例转移性结直肠癌患者接受FOLFIRI方案化疗,化疗剂量CPT-11180mg/m2静脉滴入,d1,LV200mg/m2静脉滴入2h,5-FU400mg/m2静脉推注,d1,2400mg/m2持续灌注46h,每14d为1个周期,直至疾病进展或不良反应不能耐受。每3个周期评价疗效,观察毒副反应。结果:48例患者均可评价疗效及毒副反应。客观有效率为39.58%,疾病控制率为75%。48例患者中位疾病进展时间(TTP)6.8个月,中位生存时间17.5个月,中位TTP为8.1个月。不良反应主要是迟发性腹泻、中性粒细胞减少,乙酰胆碱综合征,恶心、呕吐,多为Ⅰ～Ⅱ度,Ⅲ～Ⅳ度发生率低,且均可控制。结论:FOLFIRI方案治疗转移性结直肠癌有较高的肿瘤控制率,安全性好,毒副反应可以耐受,并可减轻临床症状,延长患者的生存期。更多还原

【Abstract】 OBJECTIVE: To evaluate the efficacy and toxicity of irinotecan(CPT-11) combined with 5-Fu/Lv in the treatment of metastatic colorectal cancer.METHODS: Forty-eight patients with metastatic colorectal cancer were treated with irinotecan 180 mg/m2 iv,d1,and leucovorin 200 mg/m2 iv two hours,and fuorouracil 400 mg/m2,iv d1,2 400 mg/m2,bolus and civ for 46 hours,14 days per cycle,until the disease progressed or side effection could not be tolerante.RESULTS: All the 48 patients could be assessable to observe the efficacy and safety.The response rate was 39.58%,disease control rate was 75%,median time to progression(TTP) were 6.8 months,and median overall survival was 17.5 months.The patients were responsed better in clinical and over six cycles,the median time to progression were 8.1 months.The majority of adverse reaction was delayed diarrhea,neutropenia,acetylcholine syndrome,nausea,and vomiting,and most of them were Ⅰ/Ⅱ degree,and Ⅲ/Ⅳ degree was seldom and could be controlled.CONCLUSION: CPT-11/5-FU/LV regimen is an effective,well tolerable and safe for metastatic colorectal cancer,and it can release clinical smptoms and prolong the patient’s life.更多还原